RPS6KB1 and mitochondrial disease: These observations are consistent with the idea that reduced S6K1 activity accounts for at least part of the beneficial effect of rapamycin in this context, and suggests that inhibition of S6K1 may be a viable therapeutic strategy for treating mitochondrial disease.